Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Research & Development (2016 - 2025)

Historic Research & Development for Iovance Biotherapeutics (IOVA) over the last 10 years, with Q3 2025 value amounting to $75.2 million.

  • Iovance Biotherapeutics' Research & Development rose 1213.97% to $75.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.5 million, marking a year-over-year increase of 410.23%. This contributed to the annual value of $282.3 million for FY2024, which is 1794.39% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Research & Development stood at $75.2 million for Q3 2025, which was up 1213.97% from $79.4 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Research & Development peaked at $87.5 million during Q3 2023, and registered a low of $62.1 million during Q2 2024.
  • Over the past 3 years, Iovance Biotherapeutics' median Research & Development value was $79.4 million (recorded in 2025), while the average stood at $78.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 2809.94% in 2024, then surged by 2783.16% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Research & Development stood at $87.5 million in 2023, then decreased by 11.84% to $77.1 million in 2024, then decreased by 2.52% to $75.2 million in 2025.
  • Its last three reported values are $75.2 million in Q3 2025, $79.4 million for Q2 2025, and $76.9 million during Q1 2025.